Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Californium-252 is a synthetic radioactive isotope of the actinide series that serves as a potent source of neutrons (Wikipedia, 2024). It is not a biological target in the traditional pharmacological sense, such as a receptor or enzyme, but is instead utilized as a therapeutic radiation source in neutron brachytherapy for treating malignancies like cervical and prostate cancers (Maruyama et al., 1985; NIH, 2023). The isotope undergoes spontaneous fission, emitting high-energy neutrons with high linear energy transfer (LET) properties. These neutrons induce lethal double-strand DNA breaks in tumor cells, which are often more effective against radioresistant or hypoxic tumors compared to standard gamma or X-ray therapies (National Cancer Institute, 2023). However, the use of Californium-252 is limited by the requirement for specialized shielding and the potential for severe radiation-induced damage to surrounding healthy tissues (Radiobiology of Californium-252, 1986).
Spontaneous fission resulting in the emission of high-energy neutrons that cause high linear energy transfer (LET) radiation damage and lethal double-strand DNA breaks in target cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Californium-252 (252Cf).